Activation of Nrf2 benefits malignant cells by promoting chemoresistance and proliferation, with aberrant elevation of Nrf2 indicating a poor prognosis in various human cancers, including lung, head and neck, breast, ovarian cancers [15–17]. This evidence concerns the gene NFE2L2 and cancer.